INDIANAPOLIS , Sept. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025 . Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at... Read More

Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations between people and their doctors Nearly four in five Americans say they would want to know if they have Alzheimer's disease before symptoms interfere with daily activities, highlighting the growing desire for open conversations and early detection 1 With the number of people aged 65... Read More

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines New offering expands Lilly Catalyze360's support for early-stage drug development INDIANAPOLIS , Sept. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug... Read More

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine plus rituximab, indicating one of the most compelling effect sizes ever observed for a single agent BTK inhibitor in a front-line CLL study BRUIN CLL-313 is the third positive Phase 3 study from the pirtobrutinib development... Read More

The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be presented at the IASLC 2025 World Conference on Lung Cancer INDIANAPOLIS , Sept. 4, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough... Read More

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit Results reinforce two years of Verzenio plus endocrine therapy as the... Read More

In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 22.9 lbs (10.5%) on the highest dose, with A1C reduced by an average of 1.8% INDIANAPOLIS , Aug. 26, 2025 /PRNewswire/... Read More

INDIANAPOLIS , Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23 rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman , M.D., Lilly chief medical officer will take part in a fireside chat at 9:15 a.m., Eastern time . A live audio webcast will be available on the "Webcasts &... Read More

INDIANAPOLIS , Aug. 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025 . Patrik Jonsson , executive vice president and president of Lilly International, will take part in a fireside chat at 9:30 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at... Read More

INDIANAPOLIS , Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31 , 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor.... Read More

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1 .5 billion to be in the range of $60 billion to $62 billion ; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00 . Pipeline progress included positive results in... Read More

In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end... Read More

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits Results from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile... Read More

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS , July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term... Read More

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending in favor of pirtobrutinib BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS , July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:... Read More

INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston -based clinical-stage company developing genetic medicines for cardiovascular disease. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering... Read More

The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer's disease in adults with... Read More

INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 8:30 a.m. Eastern time . Investors, media and the general public can access a live webcast of... Read More

INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common stock in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right... Read More

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS , July 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt),... Read More

INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025 , to shareholders of record at the close of business on August 15, 2025 . About Lilly Lilly is a medicine company turning science into healing to make life better for people... Read More

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS , June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1,... Read More

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40 in a key secondary endpoint The safety profile of orforglipron was consistent with the established GLP-1 class INDIANAPOLIS , June 21, 2025... Read More

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise INDIANAPOLIS , June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a... Read More

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499 /month or less, regardless of insurance status, under Zepbound Self Pay Journey Program In a clinical trial, adults with obesity or overweight and a weight-related medical condition taking Zepbound 15 mg lost 48 lbs (~21% weight loss) and approximately 1 in 3 on Zepbound 15 mg lost over 58 lbs (25%... Read More

INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46 th Annual Global Health Care Conference on June 10, 2025 . Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at... Read More

INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab... Read More

INDIANAPOLIS , May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85 th Scientific Sessions taking place June 20-23 in Chicago . Lilly will also host an investor event to highlight the company's... Read More

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS , May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire... Read More

INDIANAPOLIS , May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156 , an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and Verzenio ® (abemaciclib; a CDK4/6 inhibitor) will be presented at the... Read More

The authorization in Australia is for adult patients who are Apolipoprotein E-ε4 heterozygotes or non-carriers INDIANAPOLIS , May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild... Read More

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circumference reduction INDIANAPOLIS , May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of... Read More

INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years. This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the United States ,... Read More

INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide. Lilly has experienced significant growth over the past several years, particularly in the U.S. and cardiometabolic health businesses. The... Read More

INDIANAPOLIS , May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025 , to shareholders of record at the close of business on May 16, 2025 . About Lilly Lilly is a medicine company turning science into healing to make life better for people around the... Read More

INDIANAPOLIS , May 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025 . Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 11:40 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at... Read More

Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials. Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of... Read More

INDIANAPOLIS , April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the general public can access a live webcast of the... Read More

Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint The overall safety and tolerability profile of orforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies INDIANAPOLIS , April 17, 2025... Read More

In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were presented at the American College of Cardiology 2025 Scientific Sessions and simultaneously published in the New England Journal of Medicine (NEJM) INDIANAPOLIS , March 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)... Read More

New tools to connect with independent in-person and telehealth providers specializing in Alzheimer's disease are designed to increase capacity and reduce delays in diagnosis INDIANAPOLIS , March 27, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's... Read More

INDIANAPOLIS , March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30 in Chicago . In an oral presentation, Lilly, in collaboration with Foghorn Therapeutics, will present new preclinical data for... Read More

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo Positive data underscore Lilly's continued expansion across dermatologic conditions, with treatments that can improve outcomes for patients with the greatest need... Read More

Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of complete skin clearance (EASI 100 or IGA 0) and 87% achieved almost-clear skin (EASI 90) at three years with single monthly maintenance injection Additional studies demonstrated EBGLYSS significantly improved itch, skin pain, and sleep loss due to itch for a range of patients with atopic dermatitis EBGLYSS was approved in the U.S. in... Read More

INDIANAPOLIS , Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025 . Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 9:20 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at... Read More

The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor INDIANAPOLIS , Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's... Read More

Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America The company's plans represent the largest pharmaceutical manufacturing investment in U.S. history INDIANAPOLIS , Feb. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C. , plans to bolster its domestic... Read More

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS , Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program. 1 Lilly also reduced the price of the... Read More

INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45 th Annual Health Care Conference on March 4, 2025 . Jake Van Naarden , executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at... Read More

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS , Feb. 7, 2025 /PRNewswire/ -- Eli Lilly... Read More

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue (i) grew by 20% compared to Q4 2023. Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and the approval of Omvoh in the U.S. for moderately to severely active Crohn's disease. Notable recent events include the pending... Read More

INDIANAPOLIS , Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the... Read More

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remission and endoscopic response at one year, nearly 90% of patients maintained clinical remission with two years of continuous Omvoh treatment in open-label extension INDIANAPOLIS , Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and... Read More

2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance Q4 2024 revenue is expected to be approximately $13.5 billion , approximately $400 million below the low end of recently issued financial guidance The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion , growth of 32% at the midpoint compared to... Read More

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's advancements against this disease INDIANAPOLIS and BOSTON, Mass. , Jan. 13, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:... Read More

INDIANAPOLIS , Jan. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at... Read More

Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated with OSA after one year INDIANAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only... Read More

China is the fourth major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 INDIANAPOLIS , Dec. 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every... Read More

This milestone stems from the companies' collaboration to expand access to affordable insulin to one million people living with diabetes in low- to middle-income countries annually by 2030 INDIANAPOLIS and CAIRO , Dec. 17, 2024 /PRNewswire/ -- The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the... Read More

The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion VIVID-1 was the first pivotal Crohn's disease trial to show benefits in hard-to-treat symptom of bowel urgency using a patient-centric scale Omvoh will be the first treatment for Crohn's disease with results demonstrating improvements of histologic measures of... Read More

As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations As combination therapy, imlunestrant plus Verzenio significantly reduced the risk of progression or death by 43%, compared to imlunestrant alone, in all patients, regardless of ESR1 mutation status These data were published simultaneously in the New England... Read More

Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib prolonged the time to next treatment or death by a median of 23.9 months compared to 10.9 months in the control arm BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated... Read More

INDIANAPOLIS , Dec. 9, 2024 /PRNewswire/ -- Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth quarter of 2024. Additionally, for the seventh consecutive year, the board has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of... Read More

Pro Football Hall of Famer Brian Dawkins joins the team to motivate those at risk for kidney disease to prioritize complete testing LOS ANGELES , Dec. 9, 2024 /PRNewswire/ -- CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its collaboration with Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) at the 2025 Tournament of Roses ®... Read More

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity INDIANAPOLIS , Dec. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin , manufacturing facility... Read More

Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 receptor agonist in adults living with obesity without diabetes INDIANAPOLIS , Dec. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized... Read More

Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE ® Platform Demonstration of the Robust Predictive Power of CONVERGE ® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company... Read More

INDIANAPOLIS , Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024 . In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a member of Lilly's board of directors effective Dec. 31, 2024 . In 2025, Ms. Walker will collaborate with Lilly on certain... Read More

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the American Heart Association (AHA) Scientific Sessions 2024 INDIANAPOLIS , Nov. 18, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today... Read More

In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies INDIANAPOLIS , Nov. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today... Read More

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years Results suggest one new case of diabetes could be prevented for every nine patients treated with tirzepatide Participants treated with tirzepatide had an average weight reduction of 22.9% (15 mg dose) INDIANAPOLIS , Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company... Read More

INDIANAPOLIS , Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place Dec. 7-10 in San Diego . In an oral presentation, Lilly will report results from the Phase 3 BRUIN... Read More

INDIANAPOLIS , Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the San Antonio Breast Cancer Symposium (SABCS) taking place December 10-13 in San Antonio, TX. EMBER-3 is a study in estrogen receptor positive... Read More

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%. Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of... Read More

A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients receiving the standard dosing regimen used in the pivotal Phase 3 clinical trial Reduction of amyloid plaque and P-tau217 on this modified titration was... Read More

INDIANAPOLIS , Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on Dec. 10, 2024 , to shareholders of record at the close of business on Nov. 15, 2024 . About Lilly Lilly is a medicine company turning science into healing to make life better for people around... Read More

At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel urgency Mirikizumab also helped over 50% of patients with moderately to severely active Crohn's disease sustain long-term endoscopic remission for up to five years INDIANAPOLIS , Oct. 28, 2024 /PRNewswire/ -- Eli Lilly and Company... Read More

In first dedicated study of a selective IL-13 inhibitor in patients previously treated with dupilumab, the majority of patients had a history of inadequate response to dupilumab EBGLYSS also provided meaningful improvements in difficult-to-treat face and hand dermatitis The safety profile of EBGLYSS was consistent with previous Phase 3 studies and of the patients who reported eye-related events, facial dermatitis or... Read More

Great Britain is the third major market where donanemab has received approval Donanemab was first approved in the United States in July 2024 and then approved in Japan in September 2024 INDIANAPOLIS , Oct. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous... Read More

INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Compan y (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the general public can access a live webcast of... Read More

Results from Lilly's "Urgent Conversations" survey reinforce the work by the Crohn's & Colitis Foundation of America, including the "We Can't Wait" mobile bathroom finder app INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that over half (60%) of the general population struggle to find a public restroom, a... Read More

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyond endoscopy, setting a new potential standard for the evaluation of therapeutic response INDIANAPOLIS , Oct. 14, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately... Read More

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more than $23 billion since 2020... Read More

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year study The safety profile at three years was consistent with the previously published two-year results INDIANAPOLIS , Sept. 25, 2024... Read More

Japan is the second major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024 INDIANAPOLIS , Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's... Read More

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks EBGLYSS delivers long-lasting efficacy for patients through one year of treatment with a monthly maintenance dose INDIANAPOLIS , Sept. 13, 2024... Read More

Company ups manufacturing investment in Limerick by $1 billion ; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS , Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland , manufacturing site to increase production of biologic active ingredients,... Read More

Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS , Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 1 diabetes... Read More

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS , Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed... Read More

INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief... Read More

In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a second phase 3 study, QWINT-3, efsitora also delivered non-inferior A1C reduction compared to daily insulin in people with type 2 diabetes switching from daily basal injections INDIANAPOLIS , Sept. 5, 2024 /PRNewswire/ -- Eli Lilly... Read More

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa INDIANAPOLIS and CAIRO , Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand access to baricitinib to an estimated... Read More

Distributed through LillyDirect ® 's self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity INDIANAPOLIS , Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are... Read More

INDIANAPOLIS , Aug. 22, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024 . Jacob Van Naarden , executive vice president and president, Lilly Oncology, will participate in a fireside chat at 7:45 a.m. Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at... Read More

176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the 15 mg dose at end of treatment Results are consistent with the combined pharmacology of GIP and GLP-1 receptor agonism INDIANAPOLIS , Aug. 20, 2024 /PRNewswire/ -- Eli Lilly and Company... Read More

INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge , M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024 . Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of... Read More

Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a... Read More

Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs New 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway Labs' companies INDIANAPOLIS... Read More

Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding the sale of rights for Baqsimi, non-incretin revenue increased 17% worldwide and 25% in the U.S. Q2 2024 EPS increased 68% to $3.28 on a reported basis and increased 86% to $3.92 on a non-GAAP basis, both inclusive of... Read More

Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepatide significantly improved heart failure symptoms and physical limitations Tirzepatide led to 15.7% weight loss in a combined population of people with and without type 2 diabetes INDIANAPOLIS , Aug. 1, 2024 /PRNewswire/ -- Eli Lilly... Read More

INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the general public can access a live webcast of the... Read More

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass. , July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a... Read More

Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39% Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of... Read More

INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape. "Our collaboration with OpenAI represents a groundbreaking step... Read More

INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on Sept. 10, 2024 , to shareholders of record at the close of business on Aug. 15, 2024 . About Lilly Lilly is a medicine company turning science into healing to make life better for people around... Read More

In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the criteria for disease resolution as defined by apnea-hypopnea index and Epworth Sleepiness Scale measures Lilly submitted tirzepatide for the treatment of... Read More

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine INDIANAPOLIS , June 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with... Read More

INDIANAPOLIS , June 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our board of directors, leadership team and employees, I would like to thank Anat for her 23 years of outstanding service to our company," said David A. Ricks , Lilly's chair and CEO.... Read More

INDIANAPOLIS , June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024 . Seymour currently serves as the chief quality officer for Bristol Myers Squibb and succeeds Johna Norton , whose retirement after 34 years of service was announced... Read More

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS , June 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating... Read More

New $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India GENEVA , May 29, 2024 /PRNewswire/ -- During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable... Read More

INDIANAPOLIS , May 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 , 2024. Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA , will participate in a fireside chat at 4 p.m. Eastern time . A live audio webcast will be available on the "Webcasts & Presentations"... Read More

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe INDIANAPOLIS , May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today... Read More

INDIANAPOLIS , May 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ® (abemaciclib; a CDK4/6 inhibitor), Retevmo ® (selpercatinib; a rearranged during transfection [ RET ] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2024 American... Read More

Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission INDIANAPOLIS , May 21, 2024 /PRNewswire/ -- In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful... Read More

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists INDIANAPOLIS , May 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3... Read More

INDIANAPOLIS , May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external... Read More

INDIANAPOLIS , May 6, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on June 10, 2024, to shareholders of record at the close of business on May 16, 2024. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the... Read More

Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's disease in the U.S. and EU; resubmission of lebrikizumab for atopic dermatitis in the U.S.; and initiation of lepodisiran in a Phase 3 study for atherosclerotic cardiovascular disease. Q1... Read More

Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without PAP therapy, and based on these results Lilly plans to submit these data for global regulatory reviews INDIANAPOLIS ,... Read More

INDIANAPOLIS , April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the general public can access a live webcast of... Read More

INDIANAPOLIS , March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a... Read More

INDIANAPOLIS , March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of donanemab in early symptomatic Alzheimer's disease. The FDA has informed Lilly it wants... Read More

Two new films draw attention to the importance of treating obesity as a disease and the appropriate use of anti-obesity medications INDIANAPOLIS , March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines... Read More

INDIANAPOLIS , March 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego . The presentations will include new preclinical data for a fully human monoclonal anti-Nectin-4 antibody conjugated to a... Read More

INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6 , 2024. Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at... Read More

INDIANAPOLIS , Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson , group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity. "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at Lilly.... Read More

Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small... Read More

INDIANAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton , executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024 . She will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is actively underway... Read More

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations... Read More

INDIANAPOLIS , Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The conference call will begin at 10 a.m. Eastern time . Investors, media and the... Read More

Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rights Henlius to facilitate clinical development for the initiated Phase 3 MRCT (ELAINE-3) of lasofoxifene in the territory Sermonix receives upfront payment, milestone payments of up to $58M and royalties upon commercialization in the territory COLUMBUS,... Read More

INDIANAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing... Read More

INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11 , 2024. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at... Read More

INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances... Read More

INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies. These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual... Read More

People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved... Read More

INDIANAPOLIS , Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on March 8, 2024 to shareholders of record at the close of business on Feb. 15, 2024. About Lilly Lilly unites caring with discovery to create... Read More

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the intent-to-treat population and 14.9 months for women with visceral disease, however OS outcomes were not statistically significant Additional analyses of Verzenio in metastatic and early breast cancer, as well as imlunestrant... Read More

Express Scripts to add Zepbound to National Preferred Formulary INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound ™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m 2 or greater), or those who are overweight (with a BMI of 27 kg/m 2 or greater) and also have weight-related medical problems such as... Read More

INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72% INDIANAPOLIS , Dec. 1, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S.... Read More

Scheduled to open in the first half of 2024, Lilly's new Gateway Labs location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies INDIANAPOLIS , Nov. 28, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in... Read More

Alexandria and Lilly, which began their strategic relationship in 2008, are collaborating to support and accelerate the development of promising early-stage companies in the growing San Diego life science ecosystem PASADENA, Calif. , Nov. 28, 2023 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life... Read More

Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany . This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network... Read More

INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28 , 2023. Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:50 p.m., Eastern time . A live audio webcast will be available on the "Webcasts &... Read More

INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled... Read More

Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only... Read More

INDIANAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego . The presentations will provide updated, longer follow-up clinical safety and... Read More

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%. Pipeline progress included FDA approvals of Omvoh for the treatment of adults with moderately to severely active ulcerative colitis and an... Read More

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition's unknown nature and the benefits of complete testing Clinical guidelines recommend both blood and urine tests for complete screening for kidney disease: estimated glomerular filtration rate (eGFR) and urine... Read More

INDIANAPOLIS , Nov. 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Dec. 8, 2023 to shareholders of record at the close of business on Nov. 15, 2023. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the... Read More

Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one of the most disruptive symptoms Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and... Read More

INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8 , 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA ; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor... Read More

- In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) - In the Phase 3 LIBRETTO-531 study, Retevmo provided a 72% improvement in PFS compared to cabozantinib or vandetanib in patients with advanced or metastatic... Read More

INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time . Investors, media and the general public can access a live... Read More

Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% at 5 years These data reinforce two years of Verzenio plus endocrine therapy as the standard of care for these patients in this curative setting Use of Verzenio as a treatment option in this setting is supported by an NCCN®... Read More

First readout of two-year data from long-term extension study INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and... Read More

The full results of the SURMOUNT-3 trial were published in Nature Medicine and simultaneously presented at ObesityWeek ® 2023 INDIANAPOLIS , Oct. 15, 2023 /PRNewswire/ -- Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in Nature Medicine and... Read More

Mirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks The study achieved the coprimary endpoints and all major secondary endpoints versus placebo This successful Phase 3 trial will be the basis of global regulatory submissions for Crohn's disease INDIANAPOLIS , Oct. 12, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)... Read More

INDIANAPOLIS , Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ® (abemaciclib; a CDK4/6 inhibitor), Retevmo ® (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place... Read More

INDIANAPOLIS , Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and... Read More

INDIANAPOLIS , Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team. Mike Mason , executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company. Over the last two decades, Mason has served in the leadership of Lilly's Neuroscience and Diabetes businesses to achieve significant... Read More

INDIANAPOLIS , Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope... Read More

In the letter, the FDA stated no concerns about the clinical data package, safety or label for lebrikizumab INDIANAPOLIS , Oct. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema). The letter cited... Read More

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD, as established in the EMPA-KIDNEY phase III trial EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a statistically significant... Read More

INDIANAPOLIS , Aug. 29 , 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12 , 2023. Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat on Sept. 11 at 2:55 p.m., Eastern time . A live audio webcast will be... Read More

INDIANAPOLIS , Aug. 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET) -mutant medullary thyroid cancer (MTC). The study met its primary endpoint,... Read More

INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity. "Combining our current incretin portfolio,... Read More

INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better – that's the phrase that guides everything we do at Lilly," said Ruth... Read More

INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150... Read More

Revenue in Q2 2023 increased 28% as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as $579.0 million from the sale of rights for Baqsimi. Excluding revenue from Baqsimi, and COVID-19 antibodies in 2022, revenue in Q2 2023 increased 22%. Pipeline progress included positive results in the Phase 3 TRAILBLAZER-ALZ 2 study and the submissions of donanemab for traditional approval to the FDA... Read More

INDIANAPOLIS , Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab – as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). The study met its primary... Read More

Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry over 84 weeks Participants in SURMOUNT-4 achieved 21.1% weight loss during a 36-week tirzepatide lead-in period and an additional 6.7% weight loss during a 52-week continued treatment period, for a total mean weight loss of 26.0%... Read More

INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time . Investors, media and the general public can access a live... Read More

INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to... Read More

Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their risk of disease progression; nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year Additional subpopulation analyses presented live showed that those study participants at earliest stage of disease had even greater benefit,... Read More

Medicxi co-led Company's US$70 million Series A less than 2 years ago Third Medicxi portfolio exit to US biopharma in last 12 months LONDON , GENEVA and JERSEY, British Isles , July 14, 2023 /PRNewswire/ -- Medicxi, a leading European life sciences investment firm, announces that its portfolio company, Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the... Read More

INDIANAPOLIS and NEW YORK , July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to... Read More

INDIANAPOLIS , July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast will begin at 1:30 p.m. Eastern time , and remarks will primarily focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial, as well as the broader landscape in Alzheimer's disease. A live audio webcast will be available on... Read More

INDIANAPOLIS , July 6, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of an investigational use of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with chronic lymphocytic... Read More

INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases. Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell... Read More

In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% at 48 weeks Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program INDIANAPOLIS , June 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks,... Read More

INDIANAPOLIS , June 26, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Sept. 8, 2023 to shareholders of record at the close of business on Aug. 15, 2023. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the... Read More

Detailed results presented at the American Diabetes Association's ® 83 rd Scientific Sessions Lilly has completed tirzepatide's submission for chronic weight management to the FDA INDIANAPOLIS , June 24, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) tirzepatide (10 mg and 15 mg) for chronic weight management in... Read More

In additional phase 2 data, published in The Lancet, orforglipron achieved mean reduction in A1C up to 2.1% at 26 weeks in adults with type 2 diabetes Lilly is investigating orforglipron, its first nonpeptide oral GLP-1 receptor agonist, for chronic weight management in the ATTAIN phase 3 clinical program and for type 2 diabetes in the ACHIEVE phase 3 clinical program INDIANAPOLIS, June 2 3, 2023 /PRNewswire/ -- Eli Lilly... Read More

Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS , June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and... Read More

Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes New phase 2 data for retatrutide and orforglipron showcase promise of Lilly's pipeline and commitment to transform diabetes and obesity care INDIANAPOLIS , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present 40 abstracts across its diabetes and... Read More

Nationwide effort to inform people living with diabetes about how to access affordable insulin and give back to the diabetes community INDIANAPOLIS , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association ® (ADA) and Adam Duvall , American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all... Read More

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development,... Read More

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality performed numerically better than the active comparator on key secondary endpoints of the CHALLENGE-MIG trial The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with... Read More

New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients who had dose adjustments with benefit maintained at four-year follow-up; overall quality of life during the Verzenio treatment period shown to be similar to endocrine therapy alone Updated data from the Phase 1/2 BRUIN trial of Jaypirca in... Read More

INDIANAPOLIS , May 30, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023 . Anat Ashkenazi, Lilly executive vice president and chief financial officer, will participate in a fireside chat on June 12 at 4:20 p.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor... Read More

Reduced greenhouse gas emissions by 20% Improved access to Lilly insulins in the U.S. Nearly doubled patients reached in resource-limited settings through global health efforts INDIANAPOLIS , May 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to... Read More

Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel approach to treating patients with autoimmune diseases INDIANAPOLIS , May 18, 2023 /PRNewswire/ -- The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the... Read More

INDIANAPOLIS , May 11, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany , and virtually. The company-sponsored abstracts include new analyses of clinical data in approved and investigational uses... Read More

INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the medicines it makes to have a positive impact on patients and society through for-profit investments. The portfolio is aligned with Lilly's efforts to combat racial injustice and its effects... Read More

First interim Phase 2 data of an IL-23p19 antagonist in pediatric patients New analysis from the pivotal Phase 3 LUCENT-1 and LUCENT-2 studies INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative colitis (UC) that further support the efficacy and safety seen in previous pivotal studies.... Read More